Functional p53 Is Required for Effective Telomerase Inhibition in BCR-ABL-Positive CML Cells in Vitro

被引：0
|
作者：
Brassat, Ute [1 ,2 ,3 ]
Balabanov, Stefan [1 ,2 ,3 ]
Braig, Melanie [1 ,2 ,3 ]
Bali, Daniel [4 ]
Borgmann, Kerstin [4 ]
Brummendorf, Tim H. [1 ,2 ,3 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Dept Hematol & Oncol, Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Hubertus Wald Univ Canc Ctr, UCCH, Sect BMT, Hamburg, Germany
[3] Univ Med Ctr Hamburg Eppendorf, Hubertus Wald Univ Canc Ctr, UCCH, Sect Pneumol, Hamburg, Germany
[4] Univ Med Ctr Hamburg Eppendorf, Lab Radiobiol & Exp Radiooncol, Hamburg, Germany
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：214 / 215
页数：2
相关论文
共 50 条
  • [1] Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells
    Brassat, Ute
    Balabanov, Stefan
    Bali, Daniel
    Dierlamm, Judith
    Braig, Melanie
    Hartmann, Ulrike
    Sirma, Huseyin
    Gunes, Cagatay
    Wege, Henning
    Fehse, Boris
    Gontarewicz, Artur
    Dikomey, Ekkehard
    Borgmann, Kerstin
    Brumrnendorf, Tim H.
    EXPERIMENTAL HEMATOLOGY, 2011, 39 (01) : 66 - 76
  • [2] INHIBITION OF P53 IN CELLS EXPRESSING P210BCR/ABL
    LANEUVILLE, P
    BLOOD, 1993, 82 (10) : A40 - A40
  • [3] Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells
    Tauchi, T
    Nakajima, A
    Sashida, G
    Shimamoto, T
    Ohyashiki, JH
    Abe, K
    Yamamoto, K
    Ohyashiki, K
    CLINICAL CANCER RESEARCH, 2002, 8 (11) : 3341 - 3347
  • [4] BCR-ABL-POSITIVE AND BCR-ABL-NEGATIVE CLONOGENIC CELLS IN CML PATIENTS UNDERGOING LONG-TERM INTERFERON TREATMENT
    WANDL, UB
    BUTZLER, R
    NIEDERLE, N
    KLOKE, O
    MENGELKOCH, B
    BECHER, R
    SEEBER, S
    OPALKA, B
    LEUKEMIA, 1994, 8 (05) : 776 - 779
  • [5] Imatinib mesylate modulates p53 transcriptional and apoptotic activities selectively in Bcr-Abl positive cells and thereby sensitizes CML cells to Cisplatin
    Skorta, Ioanna
    Fanta, Silke
    Haubeiss, Silke
    Markwardt, Christiane
    Oren, Moshe
    Aulitzky, Walter
    van der Kuip, Heiko
    CANCER RESEARCH, 2009, 69
  • [6] Specific inhibition of hTERT by shRNA sensitizes for imatinib mesylate in BCR-ABL-positive cells.
    Sashida, G
    Tauchi, T
    Sumi, M
    Nakajima, A
    Ohyashiki, JH
    Ohyashiki, K
    BLOOD, 2004, 104 (11) : 169B - 169B
  • [7] Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors
    Radujkovic, Aleksandar
    Topaly, Julian
    Fruehauf, Stefan
    Zeller, W. Jens
    ANTICANCER RESEARCH, 2006, 26 (3A) : 2169 - 2177
  • [8] Activity of a novel telomerase inhibitor, telomestatin, against Glivec-resistant BCR-ABL-positive cells.
    Tauchi, T
    Sumi, M
    Nakajima, A
    Sashida, G
    Goto, A
    Ohyashiki, JH
    Shin-ya, K
    Ohyashiki, K
    BLOOD, 2001, 98 (11) : 616A - 616A
  • [9] Loss of p53 impedes the antileukemic response to BCR-ABL inhibition
    Wendel, Hans-Guido
    de Stanchina, Elisa
    Cepero, Enrique
    Ray, Sagarika
    Emig, Michael
    Fridman, Jordan S.
    Veach, Darren R.
    Bornmann, William G.
    Clarkson, Bayard
    McCombie, W. Richard
    Kogan, Scott C.
    Hochhaus, Andreas
    Lowe, Scott W.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (19) : 7444 - 7449
  • [10] Effective telomerase inhibition via-expression of dominant-negative HTERT leads to altered growth kinetics, elevated apoptosis and increased radiosensitivity of bcr-abl-positive k562 cells in vitro
    Brassat, Ute
    Balabanov, Stefan
    Wege, Henning
    Roessler, Daniel
    Borgmann, Kerstin
    Brummendorf, Tim
    BLOOD, 2007, 110 (11) : 862A - 862A
12345